Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical stage cell therapy company and an Australian leader in cell therapy, is pleased announce it has received a research and development (R&D) tax refund of A$3,061,205 under the Australian Government’s R&D tax incentive.
The refund is in recognition of Chimeric’s R&D activities during the 2022 financial year and will provide important funding for continued development of its portfolio of cell therapies.
The Australian Government R&D tax incentive program provides companies engaging in eligible activities with a refundable tax offset of up to 43.5%.
For more information, download the attached PDF.
Download this document
